Phase 3 N=402 Maintaining Nonsmoking: Older Smokers - 1
Tobacco Use Disorder
Primary: Participants Abstinent From Cigarettes — 31; 35; 39; 45 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=129 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
Lymphoma
Primary: Event-free Survival (EFS) — 74; 79 percentage of participants
Phase 3 N=1,102 E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Metastatic Breast Cancer
Primary: Overall Survival (OS) — 484; 440 days
Phase 3 N=720 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival — 289; 259 Days
Phase 3 N=2,224 Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
Chronic Obstructive Pulmonary Disease
Primary: Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period. — 0.94; 1.07…
Phase 3 N=85 Oral Aripiprazole Open-Label Rollover Study
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths — 61; 11; 7; 1 Participants
Phase 3 N=22 Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
Diabetes Mellitus · Chronic Kidney Disease · Diabetic Kidney Disease
Primary: Change in Urine Albumin Excretion — -21; -5 percent difference
Phase 3 N=855 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Tinea Pedis
Primary: Complete Cure of Interdigital Tinea Pedis — 16.8; 1.7 percentage of subjects — p=<0.025
Phase 3 N=53 Biological Markers of Response to Treatment in Major Depressive Disorder
Major Depressive Disorder
Primary: Serum Brain-derived Neurotrophic Factor (BDNF) Levels — 6077.270; 4393.24 pg/mL
Phase 3 N=668 Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients
Kidney Transplantation
Primary: Percentage of Participants With Efficacy Failure — 15.1; 14.0; 17.0 percentage of participants
Phase 3 N=860 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Tinea Pedis
Primary: Complete Cure of Interdigital Tinea Pedis — 26.0; 3.3 percentage of subjects — p=<0.025
Phase 3 N=319 An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain
Pain
Primary: Number of Participants With Insufficient Pain Relief After the Start of Double-Blind Period — 20; 43 number of participants — p=0.0001
Phase 3 N=610 Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
Primary: Change From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks — -4.5; -6.0 units on a scale — p=<0.001
Phase 3 N=53 Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia
Essential Thrombocythemia (ET)
Primary: Percentage of Subjects Who Responded in Platelet Count — 67.9 percentage of subjects
Phase 3 N=384 Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Cancer · Carcinoma · Castrate-Resistant Prostate Cancer
Primary: Overall Survival Through Month 24 — 174; 184 Participants